Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Clinicopathological features of patients correlated with LCP1 expression detected by immunohistochemistry

From: LCP1 correlates with immune infiltration: a prognostic marker for triple-negative breast cancer

Clinicopathological features

n

LCP1 Expression

P-value

Negative (%)

Positive (%)

Age at diagnosis

   

0.66

≤50

14

4(28.6)

10(71.4)

 

>50

15

10(66.7)

5(33.3)

 

Histological type

   

0.083

TNBC

29

14(48.3)

15(51.7)

 

Benign breast lesions

11

2(18.2)

9(81.8)

 

Tumor size

   

0.450a

≤2cm

10

6 (60.0)

4 (40.0)

 

>2cm

19

8 (42.1)

11 (57.9)

 

LN metastasis

   

0.715

YES

13

7 (53.8)

6 (46.2)

 

NO

16

7 (43.7)

9 (56.3)

 

Clinical stage

   

0.639b

I+II

23

11 (47.8)

12 (52.2)

 

III

6

3 (50.0)

3 (50.0)

 
  1. TNBC Triple-negative breast cancer, NAT Normal adjacent tissue, n Number of cases, LN Lymph node
  2. For comparison of LCP1 protein expression associated with age, tumor size, histological type, lymph node metastasis and clinical stage. Pearson's chi-squared test, Fisher's exact test and Continuous modified chi-square test were applied
  3. aTumor size comparison (≤2 cm vs. >2 cm, TNBC cohort)
  4. bClinical stage comparison (I+II vs. III,TNBC cohort)
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us